1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. LOX-1

LOX-1 

Lectin-like oxidized low-density lipoprotein receptor-1

Unlike native low-density lipoprotein (LDL), modified LDL such as oxidized, carbamylated, or acetylated LDL are not recognized by the native LDL receptor (LDL-R).1 Rather, modified LDL binds to the lectin-like oxidized LDL receptor-1 (LOX-1).Upon activation by modified LDL, LOX-1 induces endothelial dysfunction and uptake of the modified lipids.2 Endothelial dysfunction is the first stage in atherogenesis.3 Thus, the identification of LOX-1 through expression cloning as a major receptor for oxLDL in endothelial cells (ECs) supports a putative role for modified LDL in atherogenesis and has taken centre stage in cardiovascular research.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-23999
    BI-0115 99.71%
    BI-0115 是 LOX-1 的选择性抑制剂(IC50=5.4 µM),阻止细胞摄取氧化低密度脂蛋白。BI-0115 结合通过形成同二聚体配体结合域的二聚体触发受体抑制。
    BI-0115
  • HY-149922
    DKI5 Inhibitor 98.12%
    DKI5,即 (E)-N'-benzylidenehydrazinecarbothiohydrazide,是一种 LOX-1 抑制剂,IC50 值为 22.5 μM。
    DKI5
  • HY-149269
    COX-2-IN-30 Inhibitor
    COX-2-IN-30 是一种苯磺酰胺衍生物,也是一种具有口服活性的 COX/5-LOX 双重抑制剂,IC50 分别为 49 nM (COX),10.4 μM (5-LOX)。COX-2-IN-30 还抑制跨膜 hCA IXhCA XII 亚型,具有纳摩尔级 Ki 值。COX-2-IN-30 具有镇痛、抗炎和致溃疡活性,并且不显示急性胃效应。
    COX-2-IN-30
目录号 产品名 / 同用名 应用 反应物种